.Attributes Medicine, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) treatment of people with HER2+ innovative breast cancer and active or even stable human brain metastases showed constant intracranial task and also wide spread efficiency of T-DXd.